CC
ABBV icon

Cedar Capital’s AbbVie ABBV Stock Holding History

Cedar Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,030
Closed -$528K – 49
2020
Q3 		$528K Buy
+6,030
New +$568K 0.17% 124
2020
Q1 		– Sell
-4,515
Closed -$400K – 150
2019
Q4 		$400K Buy
+4,515
New +$375K 0.18% 132
2019
Q3 		– Sell
-3,551
Closed -$258K – 163
2019
Q2 		$258K Buy
3,551
+495
+16% +$38.9K 0.11% 149
2019
Q1 		$246K Sell
3,056
-129
-4% -$10.6K 0.11% 148
2018
Q4 		$294K Buy
3,185
+184
+6% +$16.2K 0.15% 129
2018
Q3 		$284K Buy
3,001
+274
+10% +$26K 0.11% 148
2018
Q2 		$253K Buy
2,727
+338
+14% +$33K 0.11% 138
2018
Q1 		$226K Buy
2,389
+189
+9% +$20.8K 0.11% 140
2017
Q4 		$213K Buy
+2,200
New +$207K 0.1% 125

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cedar Capital's ABBV Position: Q4 2020 in Review

Cedar Capital sold out of AbbVie (ABBV) in Q4 2020, closing a stake of 6,030 shares — an estimated $528K sold.

Cedar Capital first reported a position in ABBV in Q4 2017 and held it in 9 quarters. The position peaked at $528K in Q3 2020. 2,597 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

  • Cedar Capital reported no remaining AbbVie position as of Q4 2020 after selling out during the quarter.
  • Cedar Capital sold 6,030 AbbVie shares in Q4 2020, an estimated $528K.
  • Cedar Capital first reported a position in AbbVie in Q4 2017 and held it in 9 quarters.
  • Cedar Capital's AbbVie position peaked at $528K in Q3 2020.
  • 2,597 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Cedar Capital's 13F filing for Q4 2020, filed 5 Feb 2021.